Polynucleotide skin boosters (Rejuran): 2026 evidence

Polynucleotide (PN) injectables — marketed under brand names such as Rejuran, Plinest, and Innovyal Regenerative Action — have become one of the most discussed categories in aesthetic dermatology in the past five years. They are described as "skin boosters," "biorevitalizers," or "regenerative injectables." The underlying biology is genuinely interesting: short DNA fragments derived from salmon or trout sperm DNA, processed for purity and injected intradermally to stimulate fibroblast activity and dermal remodeling.

The published evidence is now substantial enough to make some balanced statements about what polynucleotides do, what they may not do, and where the data is still thin. This article summarizes the systematic review findings, the mechanism, the comparator data against hyaluronic acid boosters, the recognized adverse events, and the limitations of the current evidence base. This is not medical advice; treatment should be planned with a qualified clinician.

Nomenclature: PDRN vs. PN

A practical nomenclature point matters for anyone reading this literature. The terms "polydeoxyribonucleotide" (PDRN) and "polynucleotide" (PN) have been used interchangeably in marketing and even in some clinical papers, but they refer to DNA-derived biopolymers of different molecular weight (MW) ranges [2]. A 2025 narrative review proposed a structure-based standardization (the "Marques Polynucleotide Cutoff"):

• PDRN: small- and medium-chain DNA fragments, MW < 1500 kDa.
• PN: longer-chain DNA fragments, MW ≥ 1500 kDa.

The clinical relevance of this nomenclature is still emerging, but it matters for interpreting trials: products with different MW profiles likely behave differently in dermal remodeling and may have different optimal indications, even when both are marketed under generic terms like "polynucleotide" or "PDRN" [2].

Mechanism

Polynucleotides are proposed to act through several biological pathways:

• Adenosine A2A receptor activation: the dominant proposed mechanism for PDRN. Activation upregulates angiogenesis and tissue regeneration signaling.
• Salvage-pathway substrates: the DNA fragments provide nucleotides that can be reused by fibroblasts.
• Anti-inflammatory effects: documented in wound healing literature and consistent with reported reductions in erythema and inflammatory marker activity after PN treatment.
• Hydration/extracellular matrix support: longer-chain PN species may contribute structural water-binding effects similar to (though weaker than) hyaluronic acid.

Preclinical work in aged animal skin documents that PN treatment, alongside PDLLA and CaHA, increases expression of HSP90, HIF-1α, VEGF, and collagen synthesis pathways, with downstream improvements in measured collagen density and skin elasticity [6]. In that comparative animal model, PDLLA produced the largest effect; PN and CaHA were also positive but smaller in magnitude.

What the systematic review evidence shows

A 2024 systematic review identified nine studies of polynucleotide injectables in aesthetic medicine that met inclusion criteria, covering a total of 219 patients [1]. Quality of evidence ranged from low to moderate. Findings:

• Polynucleotide injections demonstrated statistically significant improvements in wrinkle reduction, skin texture, and elasticity in several included studies.
• Side effects were generally described as mild and transient.
• Patient satisfaction was moderate to high.
• Procedural characteristics (injection technique, depth, treatment site, interval) varied substantially across studies.

The review authors' conclusion is informative: polynucleotides offer "promising potential" but "limited consensus regarding their optimal use," and "rigorous, high-quality studies are essential to validate the effectiveness and safety." This is consistent with how the technology should be framed at consultation — supported but not yet at the level of evidence of, for example, hydroquinone in melasma or MFU-V in laxity.

Asian-skin specific evidence

A 2024 prospective study in 30 Asian subjects (mean age 40.2 ± 11.4) evaluated polynucleotides high purification technology (PN HPT) across four perceptual skin-quality categories: skin tone evenness, skin surface evenness, skin firmness, and skin glow [3]. Three intradermal injection sessions at baseline, week 4, and week 8 were followed by assessments at months 1, 2, 4, and 6.

Findings:

• Statistically significant improvements were observed in all four perceptual categories.
• No early- or late-onset adverse events were documented.
• At 6-month follow-up, 33% of patients felt "much improved" and 43% "very much improved"; 56% reported satisfaction and 44% high satisfaction.
• Mean investigator Global Aesthetic Improvement Scale (GAIS) scores at 6 months were 3.33–3.61 across categories (on a 0–5 scale).

A 2024 split-face trial in 10 Korean subjects compared needle injection with a needle-free jet injector for intradermal PN filler [4]. The jet system produced higher GAIS scores, higher patient satisfaction, and lower pain (VAS) than needle injection, with greater improvement in pore and wrinkle indices on the jet-treated side. Small sample size limits generalizability, but the data is consistent with the broader observation that delivery technique meaningfully influences outcome with intradermal biorevitalization.

Combination with hyaluronic acid

A 2025 in vitro and clinical evaluation of a PN-HA regenerative complex (high-molecular-weight polynucleotide combined with non-cross-linked hyaluronic acid) compared the combination with standalone HA-based "dermbooster" products on rheological behavior, antioxidant capacity (CUPRAC / FRAP / ORAC assays), and collagen induction in human fibroblasts at 72 hours [5]. The PN-HA combination outperformed the comparators on relative rheological behavior, intrinsic antioxidant activity, and total collagen induction. Two clinical case reports of periorbital treatment showed positive aesthetic outcomes. The data is preliminary — in vitro plus two cases is not a substitute for an RCT — but it points to where the field is moving: structured combinations of PN with HA, rather than either material in isolation.

Adverse events and limitations

Across the published trials and systematic review, the safety profile of polynucleotide injectables has been generally favorable [1][3][4]:

• Most common: injection-site reactions — erythema, mild swelling, bruising — typically transient and resolving without intervention.
• Procedural pain: material-dependent and technique-dependent; needle-free delivery may reduce it.
• Rare: nodule formation has been described less frequently than with longer-acting biostimulators (PLLA, CaHA).
• Theoretical considerations: patients with documented allergy to salmon/fish DNA-derived products should not receive these products.

Important limitations of the current evidence base [1][2]:

• Sample sizes in many published studies are modest (often fewer than 30 patients per arm).
• Heterogeneity in molecular weight, manufacturing process, brand, injection technique, depth, and interval makes cross-study comparison difficult.
• Long-term durability (beyond 6–12 months) is not well characterized.
• Head-to-head comparison with hyaluronic acid skin boosters is limited.
• Strong RCT-level evidence is still scarce relative to the breadth of marketing claims.

Patient selection

Reasonable candidates for polynucleotide injectables include:

• Patients seeking improvement in skin texture, fine wrinkles, and dermal quality rather than substantial volume change.
• Patients who have completed energy-based tightening (for example MFU-V or monopolar radiofrequency) or PLLA biostimulator treatment and want additional dermal-quality refinement.
• Patients willing to complete a multi-session protocol (commonly 2–3 sessions, 2–4 weeks apart) and accept a gradual visible effect.

Cautions or considerations:

• Patients seeking immediate visible volume change should consider hyaluronic acid filler instead.
• Patients with documented allergy to fish or salmon DNA-derived products.
• Patients with active local infection or inflammation in the treatment area.
• Pregnancy and breastfeeding (data limited).
• Patient expectations: discuss the moderate effect size and gradual onset at consultation.

Bottom line

Polynucleotide injectables are supported by a growing but still modest evidence base for improvements in skin texture, fine wrinkles, and dermal quality, with a generally favorable safety profile [1][3]. Standardization of nomenclature is still in progress, and head-to-head comparator trials with hyaluronic acid boosters are needed [2][5]. Realistic counseling — moderate effect size, gradual onset, multi-session protocol — is the most important determinant of patient satisfaction. Treatment should be planned with a board-certified dermatologist.

This article is for informational purposes and does not constitute medical advice.